Frag 176-191 record · updated 17h ago

Metabolic & appetiteSkin & aestheticsGrade B · human evidenceResearch use only

All 5 studies Jump to the evidence Compare

What is Frag 176-191 used for?

HGH Fragment 176-191, a peptide derived from the C-terminus of human growth hormone (HGH), has been primarily researched for its potential effects on fat loss and metabolic regulation. This peptide is believed to mimic some of the metabolic effects of HGH without the associated growth-promoting side effects. The mechanism of action is thought to involve the modulation of lipid metabolism and glucose uptake in adipocytes, which may contribute to its fat loss properties.

How it works: modulation of lipid metabolism and glucose uptake in adipocytes

Primarily researched for · Metabolic & appetite

Development stage

where Frag 176-191 sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 17 registered trials. It describes the research record, not a recommendation.

Identity

NameFrag 176-191

Chain length—

Molecular weight—

Formula—

Structure type—

ClassMetabolic

Research levelLimited Research

Discovered byAdded before provenance tracking · 2025

Pharmacology

Mechanismmodulation of lipid metabolism and glucose uptake in adipocytes

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence0.50

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 23, 2026. How this works →

Research stats

Total studies5

Human / animal / cellular1 / 1 / 1

Highest trial phase—

Years covered1986–2026

Latest study9d ago

Publication history

19862026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 5 Semantic Scholar UniProt

Study register

5 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Factors associated with vaccination intentions and uptake among pregnant women in the UK: A scoping review. FindingNot reported in abstract.	review	2026	Full text read0.80
Structural asymmetry in knowledge of active and passive tetanus immunization among frontline healthcare workers: Implications for adult booster policy in China. FindingOnly 12.24% (42/343) correctly identified the five-dose childhood schedule.	Human	2026	Full text read0.80
Stimulation of 2-deoxyglucose uptake in rat adipocytes by a human growth hormone fragment (hGH 4-15). FindingSignificant increase in 2-deoxyglucose uptake after hGH 4-15 injection, p < 0.005.	Animal	1986	Full text read0.70
Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives. FindingIC50 = 0.92 nM for compound 5a against dihydrofolate reductase.	In vitro	2026	Full text read0.70
Semantic Scholar search for Frag 176-191 TakeawayNot reported in abstract.	—	2010	Title only0.00

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Frag 176-191 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Frag 176-191 is discussed should be drawn from it.